ClusterOS Diagnostic Profile
Aberdeen LifeSciences
Aberdeen Life Sciences draws £306m of UKRI lead-led funding across 1,150 grants, anchored by Aberdeen (45%), James Hutton Institute (27%). 4 Companies House-traced spin-outs translate to £77m UKRI per spin-out.
The cluster shows medium-confidence "Stabilising around incumbents" and "Scaling activity instead of throughput" behaviour — research narrative is reinforced by recurring programme launches rather than narrowing toward commercial scaling, with academic capacity reabsorbing the cluster's signal.
Tap diagram to enlarge
Same data examined through five diagnostic lenses — Pipeline, Leverage, Triple Helix, Throughput, Collaboration. The interactive diagnostic is currently in private preview.
Sources: UKRI Gateway to Research (grants, outcomes); OpenAlex (publications); Companies House (spin-out lifecycle); DSIT (cluster mapping); Public investment data. Snapshot May 2026.
Stabilisation stacks · Why single interventions fail
Incumbents extract value via intermediary relationships; intermediaries protect incumbent access; incumbent stability suppresses the disruption that would reduce extraction.
"If University of Aberdeen published annual data on: (1) PhD graduate destinations (Aberdeen vs. elsewhere), (2) spin-out equity ownership by location, (3) licensing revenue retention vs. distribution, it might reduce the system's ability to absorb success signals without local retention becoming visible as a question."
Leverage hypotheses are testable perturbations, not prescriptions. Where demand-side behaviour is weakly visible, the correct move is observation — improving visibility before attempting change.
Structural resemblances · Clusters with similar stall configurations
A full ClusterOS diagnostic adds actor questionnaire data, working sessions, and anchor interviews — producing higher-confidence stall identification, board-ready stack analysis, and leverage hypotheses calibrated to your specific context.